Inside the research
Indivior Pharmaceuticals, Inc.
INDV Research profile · latest available data
Price overview
$35.82
▼ -0.18 (-0.5%)
| 52w hi | $41.83 |
|---|---|
| 52w lo | $22.73 |
| Vol | 1.10M |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.04
| Short | -0.53 |
|---|---|
| Medium | +0.07 |
| Long | +0.72 |
computed 2026-09-27
Key fundamentals
Indivior Pharmaceuticals, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
| Market cap | $4.23B |
|---|---|
| Enterprise value | $4.51B |
| Trailing P/E | 12.84x |
| Forward P/E | 7.34x |
| EV / EBITDA | 7.84x |
| P / S (ttm) | 3.18x |
| Profit margin | 26.7% |
| Revenue growth | +13.6% |
| Earnings growth | +600.0% |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.48 | |
| Sector | +0.08 | |
| Technical | -0.32 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Risk Metrics
| Beta vs SPX | 0.74 |
|---|---|
| Corr SPX | 0.25 |
| Annual vol | 47.3% |
| Annual ret | +77.6% |
| Sharpe | 1.64 |
| Max DD | -34.0% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-03 | Reg FD Disclosure, Exhibits | read |
| 2026-08-03 | Earnings Release, Reg FD Disclosure… | read |
| 2026-08-03 | Material Agreement, Reg FD Disclosure… | read |
| 2026-05-15 | Officer / Director Change, Shareholder Vote | read |
| 2026-05-04 | Reg FD Disclosure, Other Material Event… | read |
| 2026-04-30 | Earnings Release, Reg FD Disclosure… | read |
| 2026-03-17 | Material Agreement, Termination of Agreement… | read |
| 2026-03-13 | Other Material Event, Exhibits | read |
| 2026-03-12 | Other Material Event, Exhibits | read |
| 2026-02-26 | Earnings Release, Reg FD Disclosure… | read |
| 2026-01-26 | Material Agreement, Material Obligation… | read |
| 2026-01-08 | Reg FD Disclosure, Exhibits | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-05 | Anderson Woodrow D | Chief Accounting Officer | Buy | 1.50K | $54.42K |
| 2026-07-10 | Heidbreder Christian | Chief Scientific Officer | Sell | 18.59K | $764.63K |
| 2026-06-22 | Ciaffoni Joseph | Chief Executive Officer | Option exercise | 1.27M | — |
| 2026-06-22 | Ciaffoni Joseph | Chief Executive Officer | Withheld for tax | 612.55K | $23.47M |
| 2026-06-11 | Heidbreder Christian | Chief Scientific Officer | Sell | 18.59K | $707.38K |
| 2026-06-08 | Preblick Ryan | Chief Financial Officer | Sell | 36.00K | $1.36M |
| 2026-05-13 | Ryan Barbara | Grant | 6.52K | — | |
| 2026-05-13 | Kingsley Stuart A | Grant | 6.52K | — | |
| 2026-05-13 | Thompson Juliet | Grant | 6.52K | — | |
| 2026-05-13 | Humphreys Keith | Grant | 6.52K | — |
Flow & Concentration
| Insider 180d net | -$2.77M |
|---|---|
| Insider buys / sells | 1 / 3 |
| Insider bias | Sellers |
| 13F holders | 8 |
| Top-5 share | 97.7% |
| HHI | 2,671 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $204.82M | 4.99M |
| Citadel Advisors | $117.72M | 2.87M |
| Millennium Management | $86.12M | 2.10M |
| Capital Research / Capital World | $68.96M | 1.68M |
| Fidelity / FMR LLC | $16.51M | 402.42K |
| AQR Capital Management | $8.77M | 213.85K |
| Bridgewater Associates | $2.80M | 68.18K |
| T. Rowe Price Group | $39.19K | 955.11K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2024–2025 · 2 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $1.09B | +0.0% | |
| Gross profit | $957.00M | +0.0% | |
| Operating income | -$152.00M | — | |
| Net income | $210.00M | — | |
| Cash from ops | $36.00M | — |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $35.90 | $36.22 | $35.72 | $35.82 | 1.10M |
| Sep 24 | $35.71 | $36.28 | $35.57 | $36.00 | 2.22M |
| Sep 23 | $36.23 | $36.90 | $35.78 | $35.91 | 1.06M |
| Sep 22 | $35.53 | $36.63 | $35.48 | $36.19 | 2.22M |
| Sep 21 | $35.00 | $35.63 | $34.77 | $35.53 | 1.30M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →